Table 3.
Hazard ratios (95% CI) for selected sex steroid measures and incident prostate cancer.
| Multivariate* adjusted HR (95% CI) | |
|---|---|
| Total testosterone (per SD increase) | 1.02 (0.90–1.16) |
| Quartile 1 (< 301 ng/dl) | ref |
| Quartile 2 (301–391 ng/dl) | 1.01 (0.71–1.42) |
| Quartile 3 (392–494 ng/dl) | 1.07 (0.76–1.50) |
| Quartile 4 (> 494 ng/dl) | 1.00 (0.70–1.43) |
| Free testosterone (per SD increase) | 1.09 (0.96–1.23) |
| Quartile 1 (<6.34 ng/dl) | ref |
| Quartile 2 (6.34–7.77 ng/dl) | 1.23 (0.86–1.76) |
| Quartile 3 (7.78–9.21 ng/dl) | 1.42 (1.00–2.01) |
| Quartile 4 (>9.21 ng/dl) | 1.27 (0.88–1.83) |
| Total estradiol (per SD increase) | 1.03 (0.91–1.16) |
| Quartile 1 (< 17.5 pg/ml) | ref |
| Quartile 2 (17.5–21.9 pg/ml) | 0.94 (0.67–1.31) |
| Quartile 3 (22.0–27.2 pg/ml) | 1.12 (0.81–1.56) |
| Quartile 4 (>27.2 pg/ml) | 0.95 (0.67–1.34) |
| Free estradiol (per SD increase) | 1.09 (0.96–1.23) |
| Quartile 1 (< 0.42 pg/ml) | ref |
| Quartile 2 (0.42–0.51 pg/ml) | 1.24 (0.88–1.74) |
| Quartile 3 (0.52–0.63 pg/ml) | 1.44 (1.04–2.00) |
| Quartile 4 (>0.63 pg/ml) | 1.26 (0.89–1.79) |
| Estrone (per SD increase) | 1.04 (0.91–1.19) |
| Quartile 1 (< 24.9 pg/ml) | ref |
| Quartile 2 (24.9–31.7 pg/ml) | 3.56 (1.47–8.61) |
| Quartile 3 (31.8–40.4 pg/ml) | 4.16 (1.79–9.69) |
| Quartile 4 (>40.4 pg/ml) | 3.46 (1.52–7.85) |
| SHBG (per SD decrease) | 1.10 (0.96–1.27) |
| Quartile 4 (> 59.1 nM) | ref |
| Quartile 3 (45.9–59.1 nM) | 0.95 (0.66–1.35) |
| Quartile 2 (35.5–46.0 nM) | 1.16 (0.82–1.64) |
| Quartile 1 (<35.5 nM) | 1.24 (0.86–1.77) |
| T:E2 ratio (per SD increase) | 0.98 (0.86–1.11) |
| Quartile 1 (< 2.64) | ref |
| Quartile 2 (2.64–2.87) | 1.10 (0.77–1.57) |
| Quartile 3 (2.88–3.11) | 1.16 (0.81–1.65) |
| Quartile 4 (>3.11) | 1.01 (0.70–1.46) |
*
Age, race, study site, body mass index. Person-time was weighted to account for stratified sampling and the case-cohort design. Ref: reference group.
T (Testosterone), E2 (Estradiol), SHBG (Sex Hormone-Binding Globulin)